Additionally, a selective class-I HDAC inhibitor, CX101, has been demonstrated to improve the treatment response of anti-PD1 inhibitors against HCC with high HDAC1/2/3 expression [198]. This evidence concerns the gene HDAC9 and hepatocellular carcinoma.